BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Pfizer’s pipeline remains a crucial component of its long-term growth strategy. The company has made significant strides in key therapeutic areas, particularly in oncology and obesity treatments.

Pfizer Inc. (NYSE: PFE), a global pharmaceutical giant with a market capitalization of $138.21 billion, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals ...

Pfizer Inc. s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research spending and legal costs also hurt the bottom line.

Pfizer, which manufactures the branded version of Depo-Provera, had filed a petition on May 29 for coordination and mass tort designation of litigation over the drug and its generic equivalents ...

Pfizer, BioNTech challenge Moderna’s COVID vaccine patent win in U.K. Jul. 10, 2025 8:08 AM ET Pfizer Inc. (PFE) Stock, MRNA Stock, BNTX Stock By: Dulan Lokuwithana, SA News Editor 1 Comment ...

In May 2024, Pfizer settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, marking the largest resolution in the litigation.

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long ...

European Commission president Ursula von der Leyen comfortably saw off a vote of no-confidence in the European Parliament on Thursday.